259 related articles for article (PubMed ID: 25331979)
1. SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations.
Mateo F; Meca-Cortés O; Celià-Terrassa T; Fernández Y; Abasolo I; Sánchez-Cid L; Bermudo R; Sagasta A; Rodríguez-Carunchio L; Pons M; Cánovas V; Marín-Aguilera M; Mengual L; Alcaraz A; Schwartz S; Mellado B; Aguilera KY; Brekken R; Fernández PL; Paciucci R; Thomson TM
Mol Cancer; 2014 Oct; 13():237. PubMed ID: 25331979
[TBL] [Abstract][Full Text] [Related]
2. Secreted protein acidic and rich in cysteine promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells and acquisition of cancerstem cell phenotypes.
Jiang X; Liu F; Wang Y; Gao J
J Gastroenterol Hepatol; 2019 Oct; 34(10):1860-1868. PubMed ID: 31041810
[TBL] [Abstract][Full Text] [Related]
3. Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in Bone.
Sharma S; Xing F; Liu Y; Wu K; Said N; Pochampally R; Shiozawa Y; Lin HK; Balaji KC; Watabe K
J Biol Chem; 2016 Sep; 291(37):19351-63. PubMed ID: 27422817
[TBL] [Abstract][Full Text] [Related]
4. The role of SPARC in the TRAMP model of prostate carcinogenesis and progression.
Said N; Frierson HF; Chernauskas D; Conaway M; Motamed K; Theodorescu D
Oncogene; 2009 Oct; 28(39):3487-98. PubMed ID: 19597474
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of Secreted Protein, Acidic and Rich in Cysteine in Prostate Carcinogenesis: Development of a 3D Nanostructured Bone-Like Model.
Ribeiro N; Costa-Pinheiro P; Henrique R; Gomez-Lazaro M; Pereira MP; Mansur AAP; Mansur HS; Jerónimo C; Sousa SR; Monteiro FJ
J Biomed Nanotechnol; 2016 Aug; 12(8):1667-78. PubMed ID: 29342345
[TBL] [Abstract][Full Text] [Related]
6. A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.
Alcaraz LB; Mallavialle A; David T; Derocq D; Delolme F; Dieryckx C; Mollevi C; Boissière-Michot F; Simony-Lafontaine J; Du Manoir S; Huesgen PF; Overall CM; Tartare-Deckert S; Jacot W; Chardès T; Guiu S; Roger P; Reinheckel T; Moali C; Liaudet-Coopman E
Theranostics; 2021; 11(13):6173-6192. PubMed ID: 33995652
[No Abstract] [Full Text] [Related]
7. Secreted protein acidic and rich in cysteine (SPARC) induces epithelial-mesenchymal transition, enhancing migration and invasion, and is associated with high Gleason score in prostate cancer.
López-Moncada F; Torres MJ; Castellón EA; Contreras HR
Asian J Androl; 2019; 21(6):557-564. PubMed ID: 31031331
[TBL] [Abstract][Full Text] [Related]
8. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer.
Kuniyasu H; Chihara Y; Kondo H; Ohmori H; Ukai R
Oncol Rep; 2003; 10(6):1863-8. PubMed ID: 14534709
[TBL] [Abstract][Full Text] [Related]
9. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells.
Chen N; Ye XC; Chu K; Navone NM; Sage EH; Yu-Lee LY; Logothetis CJ; Lin SH
Cancer Res; 2007 Jul; 67(14):6544-8. PubMed ID: 17638862
[TBL] [Abstract][Full Text] [Related]
10. Cell-to-cell signaling influences the fate of prostate cancer stem cells and their potential to generate more aggressive tumors.
Salvatori L; Caporuscio F; Verdina A; Starace G; Crispi S; Nicotra MR; Russo A; Calogero RA; Morgante E; Natali PG; Russo MA; Petrangeli E
PLoS One; 2012; 7(2):e31467. PubMed ID: 22328933
[TBL] [Abstract][Full Text] [Related]
11. Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer.
Liu T; Qiu X; Zhao X; Yang R; Lian H; Qu F; Li X; Guo H
Oncol Rep; 2018 Feb; 39(2):659-666. PubMed ID: 29207175
[TBL] [Abstract][Full Text] [Related]
12. Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts.
Kaminski A; Hahne JC; Haddouti el-M; Florin A; Wellmann A; Wernert N
Int J Mol Med; 2006 Nov; 18(5):941-50. PubMed ID: 17016625
[TBL] [Abstract][Full Text] [Related]
13. [Screening of phosphoprotein associated with glycosphingolipid microdomains 1 (PAG1) by cDNA microarray and influence of overexpression of PAG1 on biologic behavior of human metastatic prostatic cancer cell line in vitro].
Yu WJ; Wang YW; Xie ZG; You JF; Wang JL; Cui XL; Pei F; Zheng J
Zhonghua Bing Li Xue Za Zhi; 2010 Feb; 39(2):88-94. PubMed ID: 20388373
[TBL] [Abstract][Full Text] [Related]
14. Augmented osteolysis in SPARC-deficient mice with bone-residing prostate cancer.
McCabe NP; Kerr BA; Madajka M; Vasanji A; Byzova TV
Neoplasia; 2011 Jan; 13(1):31-9. PubMed ID: 21245938
[TBL] [Abstract][Full Text] [Related]
15. Oncostatin M promotes mesenchymal stem cell-stimulated tumor growth through a paracrine mechanism involving periostin and TGFBI.
Lee MJ; Heo SC; Shin SH; Kwon YW; Do EK; Suh DS; Yoon MS; Kim JH
Int J Biochem Cell Biol; 2013 Aug; 45(8):1869-77. PubMed ID: 23735324
[TBL] [Abstract][Full Text] [Related]
16. Genomic analysis of prostate cancer stem cells isolated from a highly metastatic cell line.
Rowehl RA; Crawford H; Dufour A; Ju J; Botchkina GI
Cancer Genomics Proteomics; 2008; 5(6):301-10. PubMed ID: 19287071
[TBL] [Abstract][Full Text] [Related]
17. Bone matrix osteonectin limits prostate cancer cell growth and survival.
Kapinas K; Lowther KM; Kessler CB; Tilbury K; Lieberman JR; Tirnauer JS; Campagnola P; Delany AM
Matrix Biol; 2012 Jun; 31(5):299-307. PubMed ID: 22525512
[TBL] [Abstract][Full Text] [Related]
18. SPARC suppresses lymph node metastasis by regulating the expression of VEGFs in ovarian carcinoma.
Peng F; Zhong Y; Liu Y; Zhang Y; Xie Y; Lu Y; Zhang X; Li D
Int J Oncol; 2017 Dec; 51(6):1920-1928. PubMed ID: 29075785
[TBL] [Abstract][Full Text] [Related]
19. Notch signaling regulates tumor-induced angiogenesis in SPARC-overexpressed neuroblastoma.
Gorantla B; Bhoopathi P; Chetty C; Gogineni VR; Sailaja GS; Gondi CS; Rao JS
Angiogenesis; 2013 Jan; 16(1):85-100. PubMed ID: 22956186
[TBL] [Abstract][Full Text] [Related]
20. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions.
Sato N; Fukushima N; Maehara N; Matsubayashi H; Koopmann J; Su GH; Hruban RH; Goggins M
Oncogene; 2003 Aug; 22(32):5021-30. PubMed ID: 12902985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
